Xilio Therapeutics, Inc. develops masked immuno-oncology therapies for people living with cancer. Company news centers on its proprietary masking technology, which is designed to localize anti-tumor activity within the tumor microenvironment, and on pipeline updates for masked biologics and multi-specific I-O molecules.
Recurring developments include preclinical data for programs such as XTX601, a masked T cell engager targeting CLDN18.2, updates on XTX501, a bispecific PD-1 / masked IL-2 program, and disclosures involving masked T cell engager programs targeting PSMA and STEAP1. News also covers financial results, scientific conference presentations, inducement equity grants, board composition, and capital-structure actions.
Xilio Therapeutics (Nasdaq: XLO) appointed Cheryl R. Blanchard, Ph.D. to its board of directors, effective April 16, 2026, and announced Christina Rossi stepped down effective April 15, 2026. Dr. Blanchard brings over 30 years of leadership across biologics, devices and commercial strategy, including current service as executive chair of Anika.
The company highlighted Dr. Blanchard's experience advancing programs through U.S. clinical and regulatory pathways and her operational and commercial leadership as relevant to Xilio's masked immuno-oncology pipeline.
Xilio Therapeutics (Nasdaq: XLO) granted inducement stock options effective April 1, 2026, to two new employees totaling 3,257 shares under its 2022 Inducement Stock Incentive Plan. The options carry an exercise price of $8.48 per share and a 10-year term.
Vesting: 25% on the first anniversary of employment, then the remaining 75% in 36 equal monthly installments, subject to continued service and plan/option agreement terms.
Xilio Therapeutics (Nasdaq: XLO) reported pipeline progress and Q4/full-year 2025 results. Key milestones include a planned XTX501 IND submission mid-2026, Phase 1 start H2 2026, candidate nomination for a multi-specific masked T cell engager in Q2 2026, and AACR data for a CLDN18.2 program in April 2026. Cash and cash equivalents were $137.5M at year-end, with an expected runway through end of 2027.
Xilio Therapeutics (Nasdaq: XLO) will present new preclinical data for its masked T cell engager program targeting CLDN18.2 at the AACR Annual Meeting, April 17-22, 2026 in San Diego.
The poster, titled Discovery and Optimization of XTX601, a Masked Claudin 18.2-Targeting T Cell Engager, is scheduled for Monday, April 20, 2026, 9:00 a.m.–12:00 p.m. PST at Poster Section 10, Poster Board 11 (Abstract No. 1619).
Xilio Therapeutics (Nasdaq: XLO) will implement a 1-for-14 reverse stock split effective 5:00 p.m. ET on March 13, 2026, with split-adjusted trading beginning March 16, 2026 under ticker XLO and new CUSIP 98422T209. The split reduces outstanding shares from approximately 73.5 million to approximately 5.2 million.
The company said one primary goal is to increase its per-share market price to enable regaining compliance with Nasdaq Capital Market minimum bid price requirements. Warrants, equity awards and plan share pools will be proportionately adjusted; fractional shares will receive cash payments.
Xilio Therapeutics (Nasdaq: XLO) said company management will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on March 9, 2026 at 3:00 p.m. ET.
A live webcast will be available at the company investor site ir.xiliotx.com, with a replay archived for 30 days after the presentation.
Xilio Therapeutics (Nasdaq: XLO) granted non-qualified stock options to two new employees effective March 1, 2026 under its 2022 Inducement Stock Incentive Plan. The awards total 50,050 options with an exercise price of $0.5283 per share, equal to the February 27, 2026 closing price.
Each option has a ten-year term and vests 25% after one year, with the remaining 75% vesting in 36 equal monthly installments, subject to continued service and plan terms.
Xilio Therapeutics (Nasdaq: XLO) priced an underwritten offering of 74,780,300 pre-funded warrants at $0.5349 each, exercisable for one share at $0.0001 per share. Gross proceeds are expected to be approximately $40.0 million, with closing on or about February 13, 2026, subject to customary conditions.
Investors include Coastlands Capital (lead), Gilead Sciences, OrbiMed, Perceptive Advisors and others. Leerink Partners is sole bookrunner. Net proceeds will be used to advance product development, working capital and general corporate purposes.
Xilio Therapeutics (NASDAQ: XLO) reported $35.8 million in gross proceeds from Series B warrant exercises and estimates $137.5 million in cash and cash equivalents as of December 31, 2025. The company said this funding extends its anticipated cash runway into the second quarter of 2027. Recent program updates include a development milestone for a masked antibody program under the AbbVie collaboration and nomination of a development candidate for a wholly owned masked T cell engager targeting CLDN18.2. Corporate changes include the appointment of Sara Bonstein as chair of the board. Anticipated next milestones include an IND submission for XTX501 in mid-2026 and initial Phase 1 data for XTX501 in H2 2027, subject to FDA clearance.
Xilio Therapeutics (Nasdaq: XLO) reported clinical and financial updates on Nov 13, 2025. At SITC, Phase 2 vilastobart data showed a 40% ORR in heavily pretreated, plasma TMB-high (≥10 mut/Mb) MSS mCRC patients without liver metastases, with p=0.05 correlation between plasma TMB and response. Phase 1 efarindodekin alfa monotherapy data showed promising anti-tumor activity and tolerability; XTX501 (bispecific PD-1/masked IL-2) is advancing toward a planned IND in mid-2026. Xilio presented preclinical masked T cell engager data and nominated a PSMA development candidate. Financials: $103.8M cash as of Sept 30, 2025; Q3 collaboration revenue $19.1M; net loss $16.3M. Company expects runway into Q1 2027.